Download PDF
Thromb Haemost 1992; 67(04): 468-472
DOI: 10.1055/s-0038-1648472
Original Articles
Schattauer GmbH Stuttgart

Human Vascular Endothelial Cells Catabolise Exogenous Glycosaminoglycans by a Novel Route

Joan Dawes
*   The Heart Research Institute, Sydney, Australia
,
Duncan S Pepper
The Scottish National Blood Transfusion Service Headquarters Laboratory, Edinburgh, Scotland
› Author Affiliations
Further Information

Publication History

Received 26 March 1991

Accepted after revision 22 October 1991

Publication Date:
03 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Heparin and other anticoagulant glycosaminoglycans were radiolabelled with 125I and their catabolism by human vascular endothelial cells in culture was studied. Heparin, heparan sulphate and pentosan polysulphate were associated with the cellular fraction and incorporated into the subendothelial matrix, but dermatan sulphate was not found in either fraction. High molecular weight, fully desulphated carbohydrate chains were major catabolic products of all those glycosaminoglycans which were taken up by the cells. Pentosan polysulphate was not degraded further, but the catabolism of heparan sulphate, and to a lesser extent that of heparin, also yielded small oligosaccharides. Thus the first step in catabolism of exogenous glycosaminoglycans by human vascular endothelial cells appears to be complete desul-phation, which destroys their biological activity, followed by depolymerisation of the carbohydrate chain. This alternative to the sequential action of lysosomal exoenzymes is dependent upon binding to the cell; thus dermatan sulphate, which is not associated with the cellular fraction, is not catabolised.

 

  • References

  • 1 Marcum JA, Rosenberg RD. Heparinlike molecules with anticoagulant activity are synthesised by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126: 365-372
    CrossrefPubMedGoogle Scholar
  • 2 Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulphate administered to man - studies using a radioiodinated derivative. Thromb Haemostas 1989; 62: 945-949
    PubMedGoogle Scholar
  • 3 Hopwood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med 1990; 7: 381-104
    PubMedGoogle Scholar
  • 4 Wasteson A, Hook M, Westermark B. Demonstration of a platelet enzyme, degrading heparan sulphate. FEBS Lett 1976; 64: 218-221
    CrossrefPubMedGoogle Scholar
  • 5 Klein U, von Figura K. Partial purification and characterization of a heparan sulphate specific endoglucuronidase. Biochem Biophys Res Commun 1976; 73: 569-576
    CrossrefPubMedGoogle Scholar
  • 6 Naparstek Y, Cohen IR, Fuks Z, Vlodavsky I. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984; 310: 241-244
    CrossrefPubMedGoogle Scholar
  • 7 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
    CrossrefPubMedGoogle Scholar
  • 8 Vannucchi S, Pasquali F, Porciatti F, Chiarugi V, Magnelli L, Bianchini P. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells. Thromb Res 1988; 49: 373-383
    CrossrefPubMedGoogle Scholar
  • 9 Dawes J, Pepper DS. Catabolism of low dose heparin in man. Thromb Res 1979; 14: 845-860
    CrossrefPubMedGoogle Scholar
  • 10 MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulphate in man - catabolism of iodinated derivatives. Thromb Haemostas 1984; 51: 321-325
    PubMedGoogle Scholar
  • 11 Dawes J. Measurement of the affinities of heparins, naturally occurring glycosaminoglycans and other sulphated polymers for antithrombin III and thrombin. Anal Biochem 1988; 174: 177-186
    CrossrefPubMedGoogle Scholar
  • 12 Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 1979; 76: 5674-5678
    CrossrefPubMedGoogle Scholar
  • 13 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756
    CrossrefPubMedGoogle Scholar
  • 14 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
    CrossrefPubMedGoogle Scholar
  • 15 Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 1976; 15: 3932-3942
    CrossrefPubMedGoogle Scholar
  • 16 Barzu T, van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen J. Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 1986; 238: 847-854
    CrossrefPubMedGoogle Scholar
  • 17 Barzu T, van Rijn JLML, Petitou M, Tobelem G, Caen J. Heparin degradation in the endothelial cells. Thromb Res 1987; 47: 601-609
    CrossrefPubMedGoogle Scholar
  • 18 Perry MA, Powell GM, Wusteman FS, Curtis CG. The catabolism of intravenously injected V-[35S]sulphate in the rat. Biochem J 1977; 166: 373-379
    CrossrefPubMedGoogle Scholar
  • 19 Nakamura T, Takagaki K, Majima M, Kimura S, Kubo K, Endo M. A new type of exo-p-glucuronidase acting only on non-sulfated gly-cosaminoglycans. J Biol Chem 1990; 265: 5390-5397
    PubMedGoogle Scholar
  • 20 Muir H. Structure and enzymic degradation of mucopolysaccharides. In: Lysosomes and Storage Diseases. Hers HG, Van Hoof F. (eds) Academic Press; London: 1973. pp 79-104
    Google Scholar